The University of Queensland

Journal Article

• Chronic SARS-CoV-2, a cause of post-acute COVID-19 sequelae (Long-COVID)?

  O’Donnell, Jake S. and Chappell, Keith J. (2021). Chronic SARS-CoV-2, a cause of post-acute COVID-19 sequelae (Long-COVID)?. Frontiers in Microbiology, 12 724654, 1-4. doi: 10.3389/fmicb.2021.724654

• Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma

  Lepletier, Ailin, Madore, Jason, O'Donnell, Jake S., Johnston, Rebecca L., Li, Xian-Yang, McDonald, Elizabeth, Ahern, Elizabeth, Kuchel, Anna, Eastgate, Melissa, Pearson, Sally-Ann, Mallardo, Domenico, Ascierto, Paolo A., Massi, Daniela, Merelli, Barbara, Mandala, Mario, Wilmott, James S., Menzies, Alexander M., Leduc, Charles, Stagg, John, Routy, Bertrand, Long, Georgina V., Scolyer, Richard A., Bald, Tobias, Waddell, Nicola, Dougall, William C., Teng, Michele W. L. and Smyth, Mark J. (2020). Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma. Clinical Cancer Research, 26 (14), 3671-3681. doi: 10.1158/1078-0432.ccr-19-3925

• Cancer immunoediting and resistance to T cell-based immunotherapy

  O’Donnell, Jake S., Teng, Michele W. L. and Smyth, Mark J. (2019). Cancer immunoediting and resistance to T cell-based immunotherapy. Nature Reviews Clinical Oncology, 16 (3), 151-167. doi: 10.1038/s41571-018-0142-8

• Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome

  Liu, Jing, O’Donnell, Jake S., Yan, Juming, Madore, Jason, Allen, Stacey, Smyth, Mark J. and Teng, Michele W. L. (2019). Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome. OncoImmunology, 8 (5) e1581530, 1-12. doi: 10.1080/2162402X.2019.1581530

• RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer

  Ahern, Elizabeth, Harjunpää, Heidi, O'Donnell, Jake S., Allen, Stacey, Dougall, William C., Teng, Michele W. L. and Smyth, Mark J. (2018). RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer. OncoImmunology, 7 (6) e1431088, e1431088. doi: 10.1080/2162402X.2018.1431088

• Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy

  Liu, Jing, Rozeman, Elisa A., O’Donnell, Jake S., Allen, Stacey, Fanchi, Lorenzo, Smyth, Mark J., Blank, Christian U. and Teng, Michele W. L. (2018). Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy. OncoImmunology, 8 (2) e1546068, 1-10. doi: 10.1080/2162402X.2018.1546068

• Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy

  Glodde, Nicole, Bald, Tobias, van den Boorn-Konijnenberg, Debby, Nakamura, Kyohei, O'Donnell, Jake S., Szczepanski, Sabrina, Brandes, Maria, Eickhoff, Sarah, Das, Indrajit, Shridhar, Naveen, Hinze, Daniel, Rogava, Meri, van der Sluis, Tetje C., Ruotsalainen, Janne J., Gaffal, Evelyn, Landsberg, Jennifer, Ludwig, Kerstin U., Wilhelm, Christoph, Riek-Burchardt, Monika, Müller, Andreas J., Gebhardt, Christoffer, Scolyer, Richard A., Long, Georgina V., Janzen, Viktor, Teng, Michele W. L., Kastenmüller, Wolfgang, Mazzone, Massimiliano, Smyth, Mark J., Tüting, Thomas and Hölzel, Michael (2017). Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. Immunity, 47 (4), 789-802. doi: 10.1016/j.immuni.2017.09.012

• PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux

  O'Donnell, Jake S., Massi, Daniela, Teng, Michele W. L. and Mandala, Mario (2017). PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. Seminars in Cancer Biology, 48, 91-103. doi: 10.1016/j.semcancer.2017.04.015

• Resistance to PD1/PDL1 checkpoint inhibition

  O'Donnell, Jake S., Long, Georgina V., Scolyer, Richard A., Teng, Michele W. L. and Smyth, Mark J. (2017). Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treatment Reviews, 52, 71-81. doi: 10.1016/j.ctrv.2016.11.007

• Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease

  Liu, Jing, Blake, Stephen J., Yong, Michelle C. R., Harjunpaa, Heidi, Ngiow, Shin Foong, Takeda, Kazuyoshi, Young, Arabella, O'Donnell, Jake S., Allen, Stacey, Smyth, Mark J. and Teng, Michele W. L. (2016). Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discovery, 6 (12), 1382-1399. doi: 10.1158/2159-8290.CD-16-0577

• Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?

  O'Donnell, Jake S., Smyth, Mark J. and Teng, Michele W. L. (2016). Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?. Genome Medicine, 8 (1) 111, 111. doi: 10.1186/s13073-016-0365-1

• The voltage gated Ca2+-channel Cav3.2 and therapeutic responses in breast cancer

  Pera, Elena, Kaemmerer, Elke, Milevskiy, Michael J. G., Yapa, Kunsala T. D. S., O'Donnell, Jake S., Brown, Melissa A., Simpson, Fiona, Peters, Amelia A., Roberts-Thomson, Sarah J. and Monteith, Gregory R. (2016). The voltage gated Ca2+-channel Cav3.2 and therapeutic responses in breast cancer. Cancer Cell International, 16 (24) 24, 24. doi: 10.1186/s12935-016-0299-0